Paladin Labs Inc. and Stallergenes SA announced that they have entered into a Canadian development, promotion and distribution agreement for Oralair, Stallergenes' allergen extract immunotherapy sublingual tablets. Stallergenes and Paladin plan to submit the first product under this agreement, Oralair Grasses, for Canadian regulatory approval in 2007.

Under the terms of this agreement, Paladin will assume responsibility for Canadian clinical trials, registration, marketing, sales and distribution of Stallergenes' sublingual tablets, which include Oralair Grasses, Oralair recombinant Bet V 1 (birch) and Oralair Mites. This partnership offers Paladin the opportunity to lead the way in bringing sublingual immunotherapy, the gold standard treatment of seasonal allergies in Europe, to the Canadian market. Sublingual therapy represents a significant safety and quality of life improvement for Canadian patients compared to existing subcutaneous therapies.

"We are very pleased to team up with Paladin Labs, a company which has a demonstrated track record in developing, branding and detailing pharmaceutical specialties and with which we share a common culture of trust and performance", said Albert Saporta, chairman and CEO of Stallergenes. "This partnership is a significant milestone in Stallergenes' activities outside Europe".

"We are thrilled to partner with the leader in sublingual allergen desensitization and to bring their exciting and novel product portfolio to Canada. This agreement will build on the success of Twinject in establishing Paladin as the Canadian leader in the delivery of innovative, life-saving and patient-friendly treatment options for Canadian allergy sufferers. We are pleased that Stallergenes recognizes Paladin as being a valuable company in the advancement of this new opportunity for Canada," said Jonathan Ross Goodman, president and CEO of Paladin Labs.